Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with ES (including those with Down Syndrome) having completed the double-blind AC-055-305 / MAESTRO study as scheduled, i.e., who remained in the double-blind study up to Week 16 (whether or not they were still taking study drug at the end of this period).~Exclusion Criteria:~Subjects who prematurely discontinue double-blind study drug during the AC-055-305 / MAESTRO study due to:~* an AE assessed as related to the use of study drug,~* or elevated liver tests (related or unrelated to study drug).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan 10 mg tablet, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).